(0.08%) 5 158.75 points
(0.09%) 38 868 points
(0.00%) 18 001 points
(0.63%) $78.60
(0.47%) $2.15
(0.58%) $2 321.90
(2.00%) $27.22
(-0.05%) $964.80
(0.04%) $0.929
(-0.06%) $10.87
(-0.02%) $0.797
(0.43%) $91.84
Live Chart Being Loaded With Signals
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort...
Stats | |
---|---|
今日成交量 | 1.17M |
平均成交量 | 1.62M |
市值 | 23.61B |
EPS | TWD-0.890 ( 2023-09-30 ) |
下一个收益日期 | ( TWD0 ) 2024-05-30 |
Last Dividend | TWD0 ( N/A ) |
Next Dividend | TWD0 ( N/A ) |
P/E | -19.98 |
ATR14 | TWD0.0140 (0.03%) |
音量 相关性
Microbio Co., Ltd. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Microbio Co., Ltd. 相关性 - 货币/商品
Microbio Co., Ltd. 财务报表
Annual | 2023 |
营收: | TWD1.59B |
毛利润: | TWD380.42M (23.90 %) |
EPS: | TWD-2.11 |
FY | 2023 |
营收: | TWD1.59B |
毛利润: | TWD380.42M (23.90 %) |
EPS: | TWD-2.11 |
FY | 2022 |
营收: | TWD1.72B |
毛利润: | TWD691.30M (40.15 %) |
EPS: | TWD0.270 |
FY | 2021 |
营收: | TWD1.78B |
毛利润: | TWD739.37M (41.49 %) |
EPS: | TWD0.104 |
Financial Reports:
No articles found.
Microbio Co., Ltd.
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu. The company's Phase I clinical trial products consist of OB-318, an anti-cancer drug; MB-110 for the treatment of hepatitis C; SNP-810, an acetaminophen; FB317 to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria; and FB704A for the treatment of rheumatoid arthritis, cancer, cytokine storms, etc. It also offers FB825, which is in Phase II clinical trial for the treatment of atopic dermatitis, allergic asthma, hyper IgE syndrome, and food allergy. In addition, the company's Phase III clinical trial products comprise ON101 to treat diabetic foot ulcer; and MB-6 that acts as an adjuvant for metastatic colorectal cancer. Further, its discovery stage pipeline includes FB121 for AIDS; SNA01 to treat PD-1 related cancer; SNA02 for cancer immune therapy; and SNS01 for recurrent metastatic non-small cell lung cancer. Additionally, the company develops SNP-830 and SNP-840, a hepatotoxicity-free analgesic. It is also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was founded in 2000 and is based in Taipei, Taiwan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。